Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitravatinib + Tislelizumab vs chemotherapy in esophageal squamous cell carcinoma
CTR20222088Phase 2Terminated
- Sponsor
- BeiGene
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sitravatinib, tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by BeiGene. Started Aug 2022; status: terminated.
02
Drugs
sitravatinibtislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20222088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222088.